Alt-Support-Diabetes.org The Official Website for the Newsgroup

  • Skip to content
  • Jump to main navigation and login

Nav view search

Navigation

Search

Welcome to Alt-Support-Diabetes.org

Alt-Support-Diabetes.org is under new management.

The previous webmaster was discouraged by the lack of interest in the site, and the death of Usenet in general. The active members in the alt.support.diabetes newsgroup weren't even referring to it anymore.

The domain registration for Alt-Support-Diabetes.org was paid years in advance by Mack, who was a frequent poster on the alt.support.diabetes newsgroup and an Alt-Support-Diabetes.org Webmaster. So it doesn't make sense to have a "We're shutdown" message for the next several years. However, it's probable the site will disappear on 12 April 2024.

Some of the information here is very old as the original site was established in 2001 and much of it has never been updated. But it's still a valuable resource. So it's back.

If you would like to contribute content for the site, please contact the ASD Webmaster. Articles attributed to ASD Webmaster as contributor are those for which the true author cannot be determined. If you know who should be credited, please let us know.


Alt-Support-Diabetes (ASD) is an online support group of diabetics, their families and friends. We use this forum to freely share our personal experiences, knowledge, hopes, successes and frustrations concerning diabetes and it's impact on our lives. Currently we are using three major forums: the newsgroup alt.support.diabetes, our IRC chat room, and this website.

Newsgroups are one of the oldest parts of the internet called UseNet. It even pre-dates the World Wide Web. Currently there are over 70,000 individual newsgroups.

We encourage everyone to first read the Newsgroups FAQ. It explains the few do's and don'ts and some basic information about posting to a UseNet forum such as ours.

Disclaimer

The information made available through this web site is not intended to replace the services of a physician. It is provided for informational purposes only and is not a substitute for professional medical advice.

Diabetes News from MIT

28 June 2022

MIT news feed about: Diabetes
  • Amy Moran-Thomas receives the Edgerton Faculty Achievement Award
    The MIT anthropologist is recognized for interdisciplinary work on health, climate, and equity.
  • On planetary change and human health
    MIT anthropologist Amy Moran-Thomas reflects on the deep connection between planetary and human well-being.
  • “Living drug factories” might treat diabetes and other diseases
    Chemical engineers have developed a way to protect transplanted drug-producing cells from immune system rejection.
  • Mathematical model could lead to better treatment for diabetes
    A new model can predict which types of glucose-responsive insulin will work in humans and animals.
  • Health care innovators strive to make a difference
    A week of learning with MIT Bootcamps sparked ideas that Jal Panchal and Maria Hahn are taking forward to solve problems in health care.

Diabetes News from ScienceDaily

27 June 2022

Learn about early diabetes symptoms, diabetic diet information, diabetes care, type 1 diabetes, insulin resistance and type 2 diabetes. Read the latest medical research on diabetes.
  • Light during sleep in older adults linked to obesity, diabetes, high blood pressure
    In a sample of older men and women ages 63 to 84, those who were exposed to any amount of light while sleeping at night were significantly more likely to be obese, and have high blood pressure and diabetes compared to adults who were not exposed to any light during the night, a new study finds.
  • Diabetes: Dopamine regulates insulin secretion through a complex of receptors
    In a leap forward for diabetes research, researchers reveal that the feel-good hormone, dopamine, regulates insulin secretion through a heteromeric complex of receptors, thereby providing new targets for antidiabetic medication and therapy. The study is the first to elucidate the mechanism behind dopamine's down-regulation of insulin secretion.
  • Blood fat levels predict diabetes remission following gastric bypass surgery
    A newly developed test could help doctors more accurately predict whether individuals who undergo gastric bypass surgery will experience a remission of type 2 diabetes within two years of the procedure.
  • Researchers develop pancreatic beta-cell restoring therapy for treating type 1 diabetes
    Researchers have successfully treated type 1 diabetes in mice using pancreatic beta-cell, target-specific, chimeric antigen-receptor (CAR) regulatory T cells (Tregs), and demonstrated the feasibility of their approach to treat the human condition according to new data.
  • New way of generating insulin-producing cells
    Researchers show how a molecule that they have identified stimulates the formation of new insulin-producing cells in zebrafish and mammalian tissue, through a newly described mechanism for regulating protein synthesis.

Main Menu

  • Home
  • About ASD
  • FAQs
  • Newly Diagnosed
  • Resources

Popular Stuff

  • Hyperlipid by Petro Dobromylskyj
  • A Short History of the Alt.Support.Diabetes Newsgroup
  • Newsgroups FAQ
  • Diabetes News from MedlinePlus
  • Jennifer's Information for the Newly Diagnosed
  • Latest alt.support.diabetes Topics (Google Groups)
  • Quentin's Advice on Diet and Exercise
  • Carb Classification of Fruits and Vegetables
  • Free Veggies

Updated Stuff

  • Carb Classification of Fruits and Vegetables
  • Latest alt.support.diabetes Topics (Google Groups)
  • Diabetes News from MedlinePlus
  • Hyperlipid by Petro Dobromylskyj
  • Michael R. Eades, M.D. Blog
  • Stephan J. Guyenet, PhD -- The Science of Body Weight and Health
  • Wildly Fluctuating by Gretchen Becker
  • Dr. Bernstein’s Diabetes Solution
  • dLife

Information contained within this site is for educational purposes only. None of the participants are doctors.
We share only what we have learned by being diabetic ourselves. Please consult your doctor -- ALWAYS!
This domain expires on 12 April 2024. Contributors retain all copyright to the material submitted. For questions, comments and suggestions contact the ASD Webmaster.